Drug intelligence / Profile preview

LY3325656

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3325656 is an investigational small molecule drug developed by Eli Lilly for the treatment of type 2 diabetes mellitus. It acts as a selective agonist of G protein-coupled receptor 142 (GPR142), a target involved in glucose-dependent insulin secretion. Preclinical studies demonstrated that LY3325656 improves glycemic control and increases insulin and incretin hormone levels, making it a potential oral therapy for type 2 diabetes. The compound advanced to phase 1 clinical trials but no further development has been reported since mid-2020.

Other names: Compound 21Compound21Compound-21

Targets

GPR142 (G protein-coupled receptor 142)

Beyond the preview

Go deeper on LY3325656.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3325656.

Explore the full profile